Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials;
  • our ability to obtain necessary FDA approvals;
  • our ability to successfully commercialize VIA-2291;
  • our ability to obtain and protect our intellectual property related to our product candidates;
  • our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
  • our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item IA "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008 on file with the SEC.
  • All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


    '/>"/>
    SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
    2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
    3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
    4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
    5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
    6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
    7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
    8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
    9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
    10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
    11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
    (Date:9/16/2014)... Washington, USA (PRWEB) September 16, 2014 ... to create the features that we desire in optical ... Center at Montana State University. “As we explore surfaces ... Some of those lessons were presented in San Diego ... of Light: Light in Nature ” chaired by Shaw ...
    (Date:9/16/2014)... 16, 2014 --The emerging field of molecular electronics ... next level, enabling the construction of tiny circuits ... individual molecules would take on the roles currently ... A team of researchers from five Japanese and ... use in small-scale electronics: a molecule called picene. ...
    (Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
    Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
    ... DIEGO, April 15 Mr. Glynn has over 34 ... is well,known within the life sciences industry for his ... Most notably, Mr. Glynn,retired from Invitrogen Corporation (Nasdaq: ... company, he held several operating roles including CFO,President and ...
    ... NEW HAVEN, Conn., April 15 Vion,Pharmaceuticals, Inc. (Nasdaq: ... a,plan to achieve and sustain compliance with The Nasdaq ... of the plan., Previously, the Company announced that ... The Nasdaq Stock Market, Inc., notifying the Company,that it ...
    ... April 15 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... the,American Association for Cancer Research (AACR) in San Diego. ... of the HGF,receptor tyrosine kinase (MET), inhibits growth of ... the afternoon poster session,entitled Small Molecule Kinase Inhibitors 1 ...
    Cached Biology Technology:eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2Vion Pharmaceuticals Files Plan With Nasdaq 2Vion Pharmaceuticals Files Plan With Nasdaq 3SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3
    (Date:9/17/2014)... Trees have been growing significantly faster since the 1960s. ... barely changed, but they have accelerated -- by as ... a study carried out by scientists from Technische Universitt ... that have been continuously observed since 1870. Their findings ... Three decades ago, "forest dieback" was a hot topic, ...
    (Date:9/16/2014)... women in Australia is increased by lower socioeconomic ... September) in BJOG: An International Journal of ... high standards of living; however, existing research has ... indigenous and non indigenous Australians. , This case-control ... socioeconomic position on severe maternal morbidities associated with ...
    (Date:9/16/2014)... taught us that we inherit certain traits from our ... change how these genes play out by taking certain ... That,s exactly what a team of researchers at the ... their research of epigenetics research. , Epigenetics regulates ... DNA and histone proteins, which prevent permanent mutations or ...
    Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
    ... MCLEAN, Va., Nov. 29, 2012  Northrop Grumman Corporation (NYSE: ... proof of concept for an automated biometric information system ... will be operated for a trial period to enable ... enabled intelligence and to help determine the requirements for ...
    ... William Cooke, a professor in the UTSA College of Education ... selected to serve as the speaker of the Texas Chapter ... Tour. Over the course of a week, Cooke will deliver ... of ACSM,s Texas Chapter. "This is a big honor ...
    ... For the first time in its history, the American Society ... opening session of the ASCB,s Annual Meeting, for "An Evening ... Francisco, on Saturday, Dec. 15. Members of the ... will receive complimentary registration to the ASCB keynote addresses ...
    Cached Biology News:Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2UTSA physiologist William Cooke named 2013 Lecture Series Speaker by Texas Sports Medicine Chapter 2Public invited to 'An Evening of Science & Art' at ASCB Annual Meeting 2
    RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
    SHEEP ANTI FLECAINIDE...
    ANTI PIG LDH H4...
    RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
    Biology Products: